RAM
SRPT icon

Readystate Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Readystate Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,525
Closed -$2.62M – 731
2024
Q4 		$2.62M Buy
+21,525
New +$2.64M 0.08% 252

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Readystate Asset Management's SRPT Position: Q1 2025 in Review

Readystate Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 21,525 shares — an estimated $2.62M sold.

Readystate Asset Management first reported a position in SRPT in Q4 2024 and held it in 1 quarter. The position peaked at $2.62M in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Readystate Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 21,525 Sarepta Therapeutics shares in Q1 2025, an estimated $2.62M.
  • Readystate Asset Management first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 1 quarter.
  • Readystate Asset Management's Sarepta Therapeutics position peaked at $2.62M in Q4 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.